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1. Introduction 
In recent years, several groups have reported in vitro 
binding of [ 3 Hlcatecholamines to plasma membranes 
from a variety of tissues [ I-101. These reports have 
described some binding properties which are common- 
ly characteristic of hormone-receptor interaction (i.e. 
saturability, time- and temperature-dependence, dis- 
placement of bound hormone by unlabelled compounds 
and similar concentration ranges for the binding affinity 
and the cyclase activation). 
However, these well-documented results are impair- 
ed by the discrepancy between the inhibition of the 
catecholamine-activated cyclase by P-blockers and the 
poor or non-existant inhibition of the hormone-binding 
by such compounds. Furthermore it appears that the 
number of true /3-adrenergic receptors linked to the 
adenylate cyclase activation is much smaller than the 
total number of catecholamine binding sites [ 111. The 
non-specific sites are either linked to a hypothetical 
‘catechol’ binding moiety [9] or possibly to catechol- 
o-methyltransferase [11,121. Therefore, no definitive 
conclusion has been reached regarding the true nature 
of the fl-adrenergic receptor connected to the adenylate 
cyclase system. 
Thus in order to identify the real receptor, it appears 
necessary to suppress, in an artificial manner, the 
binding related to the catechol moiety without mod- 
ifying the adenylate cyclase activation. 
In the present report, we have studied the binding 
*Abbreviations: EGTA, ethyleneglycol - his (P-amino ethyl 
ether) N, N’-tetraacetic acid; EDTA, ethylenediamine tetraace- 
tic acid (disodium salt). 
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of catecholamines to plasma membranes prepared from 
rat adipocytes, and have shown that the non-specific 
binding of the catechol moiety to these membranes 
is markedly decreased in the presence of 1 mM EGTA* 
or 0.5 mM pyrocatechol. Under these conditions, 
activation of adenylate cyclase by norepinephrine is 
not affected, while the binding of [” Hlnorepinephrine 
is drastically reduced. The ‘residual binding’ of norepi- 
nephrine may be displaced by (-)propranolol and 
is sensitive to phospholipase A; furthermore, it can 
subsequently be related to the proportion of ‘true’ 
/3-adreno-receptor binding sites. 
2. Methods 
Plasma membranes were prepared from adipocytes 
isolated from rat epididymal fat pads as previously 
described [ 131 and were stored under liquid nitrogen 
until use. Protein concentration was measured by the 
method of Lowry et al., [14] using bovine serum 
albumine (Fraction V Pentex) as standard. 
Adenylate cyclase activity was determined by a 
modification of the method of Krishna et al., [ 151. 
The incubation mixture (50 ~1) contained 25 mM Tris- 
HCl buffer, pH 7.6, 5 mM MgCIZ, 0.4 mM [a.32P] ATP 
(C.E.A. Saclay, France), 1 mM dithiothreitol, 0.1% 
(w/v) bovine serum albumin, an ATP regenerating 
system consisting of 10 mM phosphocreatinine and 
0.1 mg/ml creatine kinase (Calbiochem, 100 units per 
mg of protein). The reaction was started by addition 
of the membrane enzyme. After incubating for 10 
minutes at 37’C, 0.1 ml of a ‘stopping’ solution 
containing 40 mM ATP, 10 mM [” HIcyclic AMP (20- 
30 X 1 O3 cpm), 20 mM EDTA, and 50 mM Tris-HCl 
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(pH 7.4) were added. Cyclic AMP was isolated by 
chromatography on neutral alumina [ 161. 
Binding assays of (-) [73H]norepinephrine (specif- 
ic activity 1 O-14 Ci/mmol from Radiochemical Center, 
Amersham) were performed at 37’C for 6 min under 
the conditions where adenylate cyclase activity was 
effective. The incubation mixture (120 ~1) contained: 
5 X lo-‘M [3 Hjnorepinephrine, 0.4 mM ATP, 5 mM 
MgCla, 1 mM dithiothreitol, 25 mM Tris-HCl (pH 7.4), 
and 70-90 ,ug of membrane protein. Membrane-bound 
radioactivity was collected on nitrocellulose filters 
(BA 85, Carl Schleicher Schtill), after washing twice 
with 5 ml of 5 mM Tris-HCl pH 7.4. Filters were 
previously preincubated in a large excess of a cold 
norepinephrine solution in order to decrease non- 
specific binding associated with the filter (blank value). 
Filters were dissolved by shaking in 10 ml of Unisolve 
(Koch Light) and counted for radioactivity. 
3. Results 
In order to overcome the problem of the specificity 
of norepinephrine binding, we have used two independent 
methods: 
1) EGTA, a specific Ca2+ chelator, suppressed about 
96% of the total catecholamine binding at 1 mM 
concentration (table 1). Under these conditions, the 
norepinephrine-enhanced adenylate cyclase activation 
was unaffected in spite of a faint modification of basal 
Table 1 
activity. Therefore a maximum of 4% of the total 
norephinephrine binding could be coupled to the 
adenylate cyclase system in fat cell membranes. 
2) The catechol compound, pyrocatechol, competed 
strongly by a separate pathway with the [3 H] norepi- 
nephrine binding sites related to the catechol moiety. 
In contrast, no effect was seen on norepinephrine- 
induced adenylate cyclase activation (table 2A). 
Addition of pyrocatechol achieved about complete 
occupancy (98%) of the catecholamine sites. Thus, the 
residual binding was about 2% of the total binding 
sites determined in the absence of pyrocatechol (table 
2A). 
(-)Propranolol, a strong /3 antagonist of the norepi- 
nephrine-enhanced adenylate cyclase activity (90% 
antagonism at 1 Om6 M), displaced 50% of the residual 
binding at the same molarity. Similar data were obtained 
with ephedrine, a sympathomimetic non-phenolic amine 
(table 2B). Therefore, these antagonists of norepinephrine 
displaced a large part of the residual binding whereas 
they did not inhibit norepinephrine binding due to the 
catechol moiety (table 2A). 
3) As shown in fig. 1, the treatment of membranes 
with a highly purified Ca2’-dependent phospholipase 
A resulted in a selective loss of the norepinephrine 
response, whereas the stimulation of the enzyme 
response to fluoride was maintained. Addition of EGTA, 
prior to that of phospholipase A, antagonized the inhi- 
bitory effect of the latter on the stimulation of adenyl- 
ate cyclase by norepinephrine and fluoride ion. 
Effect of EGTA on the adenylate cyclase activity of fat cell membranes 
and on [ 3 Hlnorepinephrine binding 
adenylate cyclase activity 
(pmol/min/mg prot. f SE) 
[ 3 H] norepinephrine binding 




EGTA 52+3 213klO 
Presence of 
EGTAlmM 38*2 154+ 8 
16.6 + 2.0 
0.8 f 0.2 
Adenylate cyclase assays were performed with 30 ~.rg of membrane protein, 
while norepinephrine binding was determined with 73 ng of membrane 
protein in the presence of 5 X lo-’ M [“Hlnorepinephrine (for details see 
Methods). 
62 
FEBS LETTERS January 1975 Volume 50, number 1 
Table 2 
Effect of pyrocatechol, (-)ephedrine and (-)propranolol on the norepinephrine-stimulated 
adenylate cyclase activity and on [’ H] norepinephrine binding to fat cell membranes 
Addition [’ H] norepinephrine binding % inhibition of norepinephrine 
(pmol bound/mg prot. t SE) stimulated adenylate cyclase 
No addition 25.8 f 1.9 0* 
(-) Ephedrine 5 X low4 M 25 f 2 70 
A (-) Propranolol 1 O- 6 M 26 + 1.5 90 
Pyrocatechol5 X 10e4 M 0.6 t 0.08 0 
Pyrocatechol 5 X 10e4 M 
+ (-) Ephedrine 10e4 M 0.4 * 0.17 
B + (-) Ephedrine 5 X 10e4 M 0.28 f 0.015 
+ (-) Propranolol 10e6 M 0.3 * 0.09 
For binding studies, the concentration of [ ‘H]norepinephrine was 5 X lo-’ M; 80 pg of membrane 
protein was used. Adenylate cyclase assays were performed with 12 c(g of membrane protein in the 
presence of 5 X 10e6 M (-)norepinephrine as described in Methods. 
* Stimulation in the presence of 5 X 10e6 M norepinephrine was 4-fold greater than the basal activity. 





Fig. 1. Fat cell membranes (210 fig of protein) were incubated 
at 37°C for 5 min in 1 mM Car&,25 mM Tris-HCI, pH 7.6 
(60 ~1 final vol) and with the indicated concentration of phos- 
pholipase A (from bee venom, Sigma, activity 1230 units/mg 
protein). Digestion was stopped by addition of 10 rcl of 14 
mM EGTA buffered with Tris at pH 7.6 and 10 #I aliquots 
(30 Irg of membrane protein) were assayed for adenylate 
cyclase activity as described in Methods, in the absence 
(o-o-o), basal, and in the presence of lo-’ M (-)norepine- 
phrine (e-e-e) or 10 mM F-(A-A-A). 
The [ 3 Hlnorepinephrine binding assay determined 
with phospholipase A-treated membranes in the presence 
of EGTA, (which both blocked the enzymic digestion 
and suppressed the binding related to the catechol 
moiety) showed a 55% decrease in the residual binding 
(table 2). 
Table 3 
Effect of phospholipase A treatment on [ 3 Hlnorepinephrine 
‘residual’ binding to fat cell membranes 
[s H] norepinephrine binding 
(pmol/mg/prot. * SE) 
Control 0.77 + 0.13 
Phospholipase A treated* 
membranes 0.43 * 0.10 
Fat cell membranes (73 c(g of protein) were incubated with 
phospholipase A (5 units per ml) for 5 min at 37°C under 
conditions similar to those described in the legend to fig. 1; 
then, EGTA was added so that its concentration was 1 mM 
final in binding assays, which were performed under the 
experimental conditions described in Methods (EGTA solution 
was buffered at pH 7.4). 
* Preliminary experiments have shown that the total [3H]nore- 
pinephrine binding measured in the absence of EGTA was not 
affected by phospholipase A treatment. 
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4. Discussion 
The principal problem involved in studies of the 
interactions of catecholamines with their receptors is 
the lack of specificity of the binding of the catechol 
moiety. In the present report, we have demonstrated 
that this difficulty can be obviated by the use of either 
the catechol compound pyrocatechol or the chelating 
agent EGTA. Each of these compounds separately 
effected a decrease of 96-98% in the toal catechol 
binding to fat cell membranes, without any modification 
of the norepinephrine-induced adenylate cyclase stimu- 
lation. In this regard, Lacombe and Hanoune [ 171 have 
recently reported a decrease of 50% in the total amount 
of epinephrine bound by rat liver plasma membranes 
in the presence of EDTA. Under the present conditions, 
it appears that a maximum of 4% of the total norepi- 
nephrine binding sites are implicated in the mechanism 
of action of biogenic amines. 
Propranolol is well established as an inhibitor of the 
lipolytic effect of epinephrine in fat cells [ 181 and of 
the epinephrine-induced stimulation of the adenylate 
cyclase system in white adipose tissue [ 191. We have 
recently established that the inhibition of adenylate 
cyclase by propranolol is strictly competitive (J. 
Pairault, unpublished data). Therefore, it appears 
likely that this ligand competes for the ‘true’ /3-adreno- 
receptor associated with the adenylate cyclase system. 
Until now, previous reports have failed to demon- 
strate the competition of propranolol for catecholamines- 
binding sites at the minimal concentration required to 
observe a 100% antagonism of the biological effect 
of catecholamines. We have shown that a fraction of the 
binding which is not displaced by pyrocatechol is 
decreased by about 50% by (-)ephedrine or (-)pro- 
pranolol. The concentration of the compounds was 
consistent with their inhibitory effect on the stimulation 
of adenylate cyclase by norepinephrine. Thus, we 
assume that the authentic /3-adrenoreceptors could 
represent 1 to 2% of the total catecholamine binding 
sites; therefore, at [3H]norepinephrine concentration 
of lo-’ M, the number of the ‘true’ sites is equivalent 
to 0.3-0.35 pmol of norepinephrine bound per milli- 
gramm of protein. Using equilibrium dialysis, Levitsky 
et al. [20] have recently reported comparable data 
for the specific binding of [3 Hlisoproterenol to turkey 
erythrocyte ghosts. 
Furthermore, we have shown that the treatment of 
fat cell membranes by phospholipase A abolished the 
stimulation of adenylate cyclase by norepinephrine 
and in addition, decreased the residual ‘binding’ to an 
extent similar to that observed with ephedrine and 
propranolol. These observations provide evidence for 
the phospholipid nature of the authentic /3-adreno- 
receptors, and are consistent with studies in other 
tissues which have suggested that phospholipids are 
important in hormone-sensitive adenylate cyclase 
systems [21,23]. 
As the catechol structure and the ethanolamine side 
chain are of critical importance for the maximal expres- 
sion of the /3-adrenergic function [8,9], it is clear that 
‘true’ /3-adrenoreceptors contain both ‘catechol’ and 
stereospecific ‘ethanolamine’ [24] binding sites which 
are each associated with the adenylate cyclase system. 
Our present results suggest hat as long as the 
‘ethanolamine’ site is occupied by an antagonist with 
an ethanolamine side chain, then the attachement of 
norepinephrine to the ‘true’ catechol moiety is prevent- 
ed. Therefore, we propose the existence of a positive 
interaction between the two types of sites suggested 
by the structure of the catecholamines. 
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